GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (STU:I9DN) » Definitions » Shiller PE Ratio

Arbutus Biopharma (STU:I9DN) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Arbutus Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma Shiller PE Ratio Historical Data

The historical data trend for Arbutus Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Shiller PE Ratio Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arbutus Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arbutus Biopharma's Shiller PE Ratio

For the Biotechnology subindustry, Arbutus Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Shiller PE Ratio falls into.



Arbutus Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Arbutus Biopharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Arbutus Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.092/131.7762*131.7762
=-0.092

Current CPI (Mar. 2024) = 131.7762.

Arbutus Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.206 100.560 -0.270
201409 -0.303 100.428 -0.398
201412 -0.219 99.070 -0.291
201503 -0.370 99.621 -0.489
201506 -0.241 100.684 -0.315
201509 -0.508 100.392 -0.667
201512 -0.092 99.792 -0.121
201603 -0.278 100.470 -0.365
201606 -2.198 101.688 -2.848
201609 -0.330 101.861 -0.427
201612 -3.877 101.863 -5.016
201703 -0.318 102.862 -0.407
201706 -0.294 103.349 -0.375
201709 -0.176 104.136 -0.223
201712 -0.566 104.011 -0.717
201803 -0.292 105.290 -0.365
201806 0.009 106.317 0.011
201809 -0.420 106.507 -0.520
201812 -0.325 105.998 -0.404
201903 -0.416 107.251 -0.511
201906 -0.407 108.070 -0.496
201909 -1.362 108.329 -1.657
201912 -0.414 108.420 -0.503
202003 -0.226 108.902 -0.273
202006 -0.222 108.767 -0.269
202009 -0.229 109.815 -0.275
202012 -0.189 109.897 -0.227
202103 -0.176 111.754 -0.208
202106 -0.191 114.631 -0.220
202109 -0.204 115.734 -0.232
202112 -0.133 117.630 -0.149
202203 -0.100 121.301 -0.109
202206 -0.095 125.017 -0.100
202209 -0.121 125.227 -0.127
202212 -0.132 125.222 -0.139
202303 -0.093 127.348 -0.096
202306 -0.092 128.729 -0.094
202309 -0.112 129.860 -0.114
202312 -0.110 129.419 -0.112
202403 -0.092 131.776 -0.092

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arbutus Biopharma  (STU:I9DN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Arbutus Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (STU:I9DN) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma (STU:I9DN) Headlines

No Headlines